PALI-2108 — IND submission
2H 2026
IND submission for Phase 2 CD trial expected in 2H 2026Source filing
PALI biotech catalysts & pipeline
PALISADE BIO INC · Data as of 2026-10-25
Upcoming catalysts
ALTO-100 — Topline data
mid-2027
Notwithstanding, ALTO-100 is being evaluated as an adjunctive treatment in a Phase 2b study in bipolar depression with topline data expected in mid-2027.Source filing
PALI-2108 — Topline data
H2 2027
Enrollment of first patient for Phase 2 ASCENTRA-UC trial of PALI-2108 expected in the second half of 2026; primary efficacy results expected in the second half of 2027Source filing
PALI-2108 — Topline data
early 2028
Primary efficacy readout expected in early 2028Source filing